[go: up one dir, main page]

IL122296A0 - Quinolizinone type compounds - Google Patents

Quinolizinone type compounds

Info

Publication number
IL122296A0
IL122296A0 IL12229696A IL12229696A IL122296A0 IL 122296 A0 IL122296 A0 IL 122296A0 IL 12229696 A IL12229696 A IL 12229696A IL 12229696 A IL12229696 A IL 12229696A IL 122296 A0 IL122296 A0 IL 122296A0
Authority
IL
Israel
Prior art keywords
type compounds
quinolizinone
quinolizinone type
compounds
type
Prior art date
Application number
IL12229696A
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL122296A0 publication Critical patent/IL122296A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/68One oxygen atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL12229696A 1995-06-06 1996-06-05 Quinolizinone type compounds IL122296A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46915995A 1995-06-06 1995-06-06
US63811296A 1996-05-29 1996-05-29
PCT/US1996/008991 WO1996039407A1 (en) 1995-06-06 1996-06-05 Quinolizinone type compounds

Publications (1)

Publication Number Publication Date
IL122296A0 true IL122296A0 (en) 1998-04-05

Family

ID=27042662

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12229696A IL122296A0 (en) 1995-06-06 1996-06-05 Quinolizinone type compounds

Country Status (8)

Country Link
EP (1) EP0871628A1 (en)
JP (1) JPH11510478A (en)
KR (1) KR19990022524A (en)
AU (1) AU6153096A (en)
CA (1) CA2222322A1 (en)
IL (1) IL122296A0 (en)
MX (1) MX9709416A (en)
WO (1) WO1996039407A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259927A1 (en) 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
US5693813A (en) * 1997-02-26 1997-12-02 Abbott Laboratories Process for preparation of 4H-4-oxo-quinolizine-3-carboxylic acid
KR100241673B1 (en) * 1997-08-09 2000-03-02 김충섭 Quinolizine Carboxylic acid Derivatives
RU2193558C2 (en) 1997-09-15 2002-11-27 Дзе Проктер Энд Гэмбл Компани Derivatives of quinolone and pharmaceutical composition based on thereof
EP1115724A1 (en) 1998-09-21 2001-07-18 Shire Biochem Inc. Quinolizinones as integrin inhibitors
DK1134219T3 (en) * 1998-11-24 2005-10-17 Daiichi Seiyaku Co Cucloalkyl-substituted aminomethylpyrrolidine derivatives
KR100768034B1 (en) 1999-03-17 2007-10-17 다이이찌 세이야꾸 가부시기가이샤 Medicinal composition
AU1996301A (en) * 1999-12-14 2001-06-25 Neurosearch A/S Novel heteroaryl-diazabicycloalkanes
DE19962470A1 (en) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Use of chemotherapy drugs
SE0100326D0 (en) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
EP1437354B1 (en) * 2001-09-28 2008-08-13 Sato Pharmaceutical Co. Ltd. 4-oxoquinolizine antimicrobials having 2-pyridone skeleton as partial structure
US6900224B2 (en) * 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
WO2005033108A1 (en) * 2003-09-22 2005-04-14 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7569599B2 (en) 2003-12-12 2009-08-04 Daiichi Pharmaceutical Co., Ltd. Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates
US7977346B2 (en) 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
WO2007110835A2 (en) 2006-03-28 2007-10-04 The Procter & Gamble Company A coupling process for preparing quinolone intermediates
MY148393A (en) 2006-03-28 2013-04-15 Taigen Biotechnology Co Ltd Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
WO2008082009A2 (en) * 2007-01-05 2008-07-10 Daiichi Sankyo Company, Limited Fused substituted aminopyrrolidine derivative
CN101622240B (en) * 2007-01-05 2014-07-23 第一三共株式会社 Fused Substituted Aminopyrrolidine Derivatives
US8124807B2 (en) 2007-12-26 2012-02-28 Msd K.K. Sulfonyl-substituted 6-membered ring derivative
JP5433992B2 (en) * 2008-06-26 2014-03-05 Dic株式会社 Method for producing fluorochromanol derivative
JP5433996B2 (en) * 2008-07-10 2014-03-05 Dic株式会社 Method for producing fluorophenol derivative
EP2423211B1 (en) * 2009-04-20 2014-04-16 Kaneka Corporation Processes for producing (1s,6s)- or (1r,6r)-cis-2,8-diazabicyclo[4.3.0]nonane and intermediate thereof
US8796297B2 (en) 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
JP5487425B2 (en) * 2009-09-11 2014-05-07 毅 野田 Optically active 2-substituted-3-aminopiperidine derivatives and production method
ME02437B (en) 2009-10-23 2016-09-20 Janssen Pharmaceutica Nv DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLE AS OREXIN RECEPTOR MODULATORS
EP2812004B1 (en) * 2012-02-10 2018-06-27 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
ES2879995T3 (en) 2015-12-10 2021-11-23 Ptc Therapeutics Inc Methods for treating Huntington's disease
IL288321B2 (en) 2016-03-10 2025-08-01 Janssen Pharmaceutica Nv Methods for treating depression using orexin-2 receptor antagonists
CN106543170B (en) * 2016-10-27 2018-02-23 丹诺医药(苏州)有限公司 The carboxylate of 8 chlorine, 1 cyclopropyl, 7 fluorine, 9 methyl, 4 oxygen, 4 hydrogen quinolizine 3 and its synthetic method
EA201991309A1 (en) 2016-11-28 2019-11-29 RNA SPLICING MODULATION METHODS
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
AU2018284853A1 (en) 2017-06-14 2019-12-19 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
MX2019015578A (en) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Methods for treating huntington's disease.
CN111163838B (en) 2017-06-28 2023-03-28 Ptc医疗公司 Methods for treating huntington's disease
MX2020009957A (en) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compounds for treating huntington's disease.
EA202092899A1 (en) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE
SG11202012674PA (en) 2018-06-27 2021-01-28 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2025143096A1 (en) * 2023-12-29 2025-07-03 キッセイ薬品工業株式会社 Nitrogen-containing condensed ring compound

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081891C (en) * 1990-05-02 1999-03-16 Daniel T. Chu Quinolizinone type compounds
JPH09503783A (en) * 1993-10-14 1997-04-15 アボツト・ラボラトリーズ Quinolidinone type compound

Also Published As

Publication number Publication date
EP0871628A1 (en) 1998-10-21
AU6153096A (en) 1996-12-24
JPH11510478A (en) 1999-09-14
CA2222322A1 (en) 1996-12-12
KR19990022524A (en) 1999-03-25
MX9709416A (en) 1998-07-31
WO1996039407A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
IL122296A0 (en) Quinolizinone type compounds
GB9508810D0 (en) Compounds
GB9500691D0 (en) Compounds
GB9504910D0 (en) Compounds
GB9504948D0 (en) Compounds
GB9512129D0 (en) Compounds
GB9520489D0 (en) Compounds
GB9602305D0 (en) Compounds
GB9502783D0 (en) Compounds
GB9504802D0 (en) Compounds
GB9508874D0 (en) Compounds
GB9518952D0 (en) Compounds
GB9520050D0 (en) Compounds
GB9520354D0 (en) Compounds
GB9520360D0 (en) Compounds
GB9520362D0 (en) Compounds
GB9520628D0 (en) Compounds
GB9521504D0 (en) Compounds
GB9522045D0 (en) Compounds
GB9500688D0 (en) Compounds
GB9501357D0 (en) Compounds
GB9501580D0 (en) Compounds
GB9501581D0 (en) Compounds
GB9506168D0 (en) Compounds
GB9502784D0 (en) Compounds